Brief report by Dmitri V. Kravtsov et al.
February 22, 2005
 originally published online doi:10.1182/blood-2004-05-1864
2005 105: 4671-4673
 
 
Dmitri V. Kravtsov, Paul E. Monahan and David Gailani
 
deficiency
A classification system for cross-reactive material-negative factor XI
 
http://www.bloodjournal.org/content/105/12/4671.full.html
Updated information and services can be found at:
 (2494 articles) Hemostasis, Thrombosis, and Vascular Biology     
 (3953 articles) Clinical Trials and Observations     
 (1772 articles) Brief Reports     
Articles on similar topics can be found in the following Blood collections
http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests
Information about reproducing this article in parts or in its entirety may be found online at:
http://www.bloodjournal.org/site/misc/rights.xhtml#reprints
Information about ordering reprints may be found online at:
http://www.bloodjournal.org/site/subscriptions/index.xhtml
Information about subscriptions and ASH membership may be found online at:
  
Copyright 2011 by The American Society of Hematology; all rights reserved.
of Hematology, 2021 L St, NW, Suite 900, Washington DC 20036.
Blood (print ISSN 0006-4971, online ISSN 1528-0020), is published weekly by the American Society
For personal use only. on October 31, 2014.  by guest    www.bloodjournal.org From  For personal use only. on October 31, 2014.  by guest    www.bloodjournal.org From HEMOSTASIS, THROMBOSIS,AND VASCULAR BIOLOGY
Brief report
Aclassiﬁcation system for cross-reactive material-negative factor XI deﬁciency
Dmitri V. Kravtsov, Paul E. Monahan, and David Gailani
The bleeding disorder associated with
factor XI (fXI) deﬁciency is typically inher-
ited as an autosomal recessive trait. How-
ever, some fXI mutations may be associ-
atedwithdominantdiseasetransmission.
FXI is a homodimer, a feature that could
allow certain mutations to exert a domi-
nant-negative effect on wild-type fXI se-
cretion through heterodimer formation.
We describe 2 novel fXI mutations
(Ser225Phe and Cys398Tyr) that form in-
tracellular dimers, are secreted poorly,
and exhibit dominant-negative effects on
wild-type fXI secretion in cotransfection
experiments. Available data now suggest
that mutations associated with cross-
reactive material-negative fXI deﬁciency
fall into 1 of 3 mechanistic categories: (1)
mutationsthatreduceorpreventpolypep-
tide synthesis, (2) polypeptides that fail to
form intracellular dimers and are retained
in cells as monomers, and (3) polypep-
tides that form dimers that are not se-
creted. The latter category likely ac-
counts for many cases of dominant
disease transmission. (Blood. 2005;105:
4671-4673)
© 2005 by TheAmerican Society of Hematology
Introduction
The homodimeric plasma protein factor XI (fXI) is the precursor of
the coagulation protease fXIa.1,2 FXI dimer formation, which is
unique among coagulation proteases,1-3 is a prerequisite for fXI
secretion from cells.4,5The noncatalytic portion of the fXI polypep-
tide contains 4 repeats called apple domains (A1-A4 from the
N-terminus).2 The A4 domain is the primary mediator of dimer
formation,6 and mutations inA4 that interfere with dimerization are
associated with retention of fXI monomer within cells and low
plasma fXI levels.4,5 The dimeric structure has implications for
inheritance patterns in congenital fXI deﬁciency. This disorder is
prevalent in Ashkenazi Jews, in whom 2 point mutations,
Glu117Stop and Phe283Leu, predominate.7,8 These mutations are
associated with an apparently autosomal recessive bleeding disor-
der, as heterozygotes are generally asymptomatic.7,9 The situation
is not as clear for fXI-deﬁcient patients not of Jewish ancestry, in
whom no single mutation predominates. There are reports of
heterozygotes for fXI mutations with plasma fXI levels of less than
0.2 U/mL, a range commonly seen in homozygous or compound
heterozygous fXI-deﬁcient Jewish patients.5,10-12 In 2 cases, muta-
tions were identiﬁed (Gly400Val and Trp569Ser) that exert domi-
nant-negative effects on fXI secretion in transfection experiments,
probably through formation of nonsecretable heterodimers.5 It is
not clear whether these cases are unusual or represent a common
mechanism in fXI deﬁciency. Prompted by these data, and personal
observations of patients with fXI levels in an intermediate range
(20%-30% of normal) between those typically seen in homozygous
and heterozygous Jewish patients, we analyzed the effects of 2
novel fXI mutations on wild-type fXI secretion. The results, in
conjunction with prior work, suggest a simple classiﬁcation system
for cross-reactive material-negative (CRM) fXI deﬁciency.
Study design
Patients
Patient 1 is a 34-year-old man with a history of left knee hemarthrosis and
frequent epistaxis. His fXI levels range from 22% to 30% of normal. His 2
children have fXI levels of 25% to 37%.All 3 individuals are heterozygous
f o raC T change in fXI exon 7, resulting in a Ser225 to Phe substitution.
Patient 2 is a 38-year-old woman with heavy postpartum bleeding,
idiopathic hematuria, and low fXI activity (25%-39%). She is heterozygous
f o raG A change in exon 11, resulting in a Cys398 to Tyr substitution. A
homozygote and 2 heterozygotes for Cys398Tyr were previously reported
in unrelated families.13 Plasma fXI antigen levels for all patients match
plasma fXI activity. Procedures for obtaining blood for DNAextraction and
factor XI gene analysis were approved by the Institutional Review Boards
of Vanderbilt University and the University of North Carolina. Informed
consent was obtained according to the Declaration of Helsinki.
Transient transfections
Point mutations for Ser225Phe or Cys398Tyr were introduced into the
wild-type fXI (fXI-WT) cDNAin pJVCMVas described.14Transfections of
293 ﬁbroblasts, growing in Dulbecco modiﬁed Eagle medium (DMEM)
with sodium pyruvate, L-glutamine, and 5% fetal bovine serum, were
performed in 6-well culture plates using SuperFect reagent (Qiagen,
Valencia,CA).5Singletransfectionsused80ng,andcotransfections160ng,
of fXI/pJVCMV construct. All transfections included 40 ng Renilla
luciferase (pRL-CMV) vector (Promega, Madison, WI) to control for
transfection efﬁciency, and empty pJVCMV to bring total DNA to 2
g/transfection. Media were collected 67 hours after transfection, and cell
lysates were prepared using a Dual Luciferase Reporter kit (Promega).
Luciferase activity was measured on a Monolight 2010 luminometer
(Analytical Luminescence, San Diego, CA). FXI in media and lysates was
measured by enzyme-linked immunosorbent assay (ELISA) using goat
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Hamilton, Ontario).5 Results were corrected for variation in transfection
efﬁciency using the luciferase signals and reported as relative fXI levels.
The mean for fXI-WT was assigned a value of 100%.
Western blots of intracellular fXI
Baby hamster kidney (BHK) ﬁbroblasts were transfected with pLg-fXI-IN
constructs,15 and stably transfected clones were selected by addition of
G418 (500 g/mL) to media. pLg-fXI-IN constructs use a cytomegalovirus
promoter to generate a single mRNA encoding both fXI and a neomycin
resistance marker (N) separated by an internal ribosomal entry site (I).
Supernatants from cells lysed by sonication were size fractionated on 7.5%
polyacrylamide–sodium dodecyl sulfate (SDS) gels, followed by Western
blotting using goat anti–human fXI polyclonal antibodies (described under
“Transient transfections”) and chemiluminescence.
Results and discussion
In single transient transfections, fXI-Phe225 and fXI-Tyr398 levels
in media are low (8.8%  2.8% and 1.4%  1.8%, respectively)
compared with fXI-WT (100%  11.7%) (Figure 1A), with results
for fXI-Tyr398 similar to negative control (1.9%  1.7%). This
appears to be due to reduced secretion, as fXI-Phe225 and
fXI-Tyr398levelsinlysates(99.4%  10.3%and65.7%  29.9%)
are comparable to fXI-WT (100%  18.3%) (Figure 1B). Cotrans-
fection of fXI-WT with fXI-Phe225 or fXI-Tyr398 results in
reduced fXI in media (36.6%  8.5% and 50.2%  6.5%, respec-
tively) compared with fXI-WT control, with little change in
intracellular protein (115.3%  18.0% and 81.1%  8.7%). In
comparison, cotransfection of fXI-WT with an additional equal
amount of fXI-WTconstruct results in modest increases in secreted
and intracellular antigen (121.1%  12.8% and 144.8%  18.2%).
Stably transfected BHK lines were prepared for fXI-WT, fXI-
Phe225, and fXI-Tyr398, as well as the previously reported
dominant-negative mutant fXI-Ser569 and the dimerization-
defective mutant fXI-Glu350.5 Only fXI-WT was secreted to a
signiﬁcant extent (data not shown). Western blots of intracellular
protein (Figure 1C-D) show that fXI-Phe225, fXI-Tyr398, and
fXI-Ser569 form intracellular dimers similar to fXI-WT, indicating
that poor secretion of these mutants is not due to a failure to form
dimers, as in the case of fXI-Glu350.
Most fXI-deﬁcient patients have proportional decreases in
plasma activity and antigen (CRM deﬁciency).9,10,16 Observations
over the past 40 years suggest that fXI deﬁciency in Jewish patients
is inherited primarily as a recessive condition,9,10,17 and our
understanding of the mutations involved is consistent with this
interpretation (Figure 2).5,18 However, the multimeric structure of
fXI, like those of von Willebrand factor19 and ﬁbrinogen,20 is
conducive to CRM dominant forms of disease through formation
of nonsecretable heteromultimers. Hypothetically, any fXI muta-
tion that interferes with protein secretion, but not dimer formation,
could inhibit normal fXI polypeptide secretion. If the mutant
polypeptide is expressed at a high enough level, the effect on
plasma fXI level may be great enough to compromise hemostasis.
The data herein indicate that this mechanism, previously proposed
Figure 1. Transfections of 293 cells with fXI/pJVCMV expression constructs.
FXI antigen levels in media (A) and cell lysates (B) of transient transfections are
shown. 293 ﬁbroblasts were transfected with 80 ng expression construct for individual
transfections (columns 1-3) and 80 ng fXI-WT expression construct plus 80 ng
construct to be tested for cotransfections (columns 4-6). The negative control in
column 7 contains empty pJVCMV vector. Shown are means and standard deviations
for 6 separate transfections, each measured in triplicate by ELISA and corrected for
transfection efﬁciency by Renilla luciferase assay. The mean for single fXI-WT
transfections was assigned a value of 100%. Lane (1) fXI-WT, (2) fXI-Phe225, (3)
fXI-Tyr398, (4) fXI-WT  fXI-WT, (5) fXI-WT  fXI-Phe225, (6) fXI-WT  fXI-Tyr398,
(7) pJVCMV without cDNA. Western blots for fXI in lysates of BHK cells transfected
with pLg-fXI-IN constructs. Samples from stably transfected cell lines were run on a
7.5% polyacrylamide-SDS gel, followed by Western blotting with goat anti–human fXI
polyclonal antibody. (C) Samples are (1) conditioned media from fXI-WT cells and
lysates from cells transfected with (2) fXI-WT, (3) fXI-Phe225, (4) fXI-Glu350, and (5)
untransfected BHK cells. (D) Samples are (1) conditioned media from fXI-WT cells
and lysates from cells transfected with (2) fXI-WT, (3) fXI-Tyr398, (4) fXI-Ser569, and
(5) untransfected BHK cells. Positions of dimeric (D) and monomeric (M) fXI are
indicated to the right of each panel, and positions of molecular mass standards in
kilodaltons are shown on the left. The ratio of dimer to monomer varied between
experiments. Note that, with the exception of fXI-Glu350, which does not dimerize,5
patterns for mutants match the wild-type pattern.
Figure 2. Proposed mechanisms for CRM-negative fXI deﬁciency.
FXI dimers and monomers within circles at the top of the ﬁgure represent
intracellular protein, arrows indicate secretion, and FXI dimers below the
arrowsrepresentplasmafXI.Thepercentageofactivityandantigenvalues
shown are what would be expected, on average, for different mechanisms.
Mutationsincategory1preventorreducesynthesisoffXIpolypeptide,and
heterozygosity for such a mutation would not affect the product of the
normal allele. Glu117Stop is the most common example from this group.
Category 2 contains polypeptides that are synthesized but dimerize poorly,
resultinginintracellularretentionofmonomers.Heterozygosityforthistype
of mutant would have little effect on secretion of product from the normal
allele, because the mutant would dimerize poorly with wild-type polypep-
tide, and heterodimers that do form are secreted. The diagram shows the
expected result for the most common mutation in this group, Phe283Leu,
which has a partial defect in dimerization. Category 3 includes polypep-
tides that are synthesized and form dimers, but that are secreted poorly in
homodimeric or heterodimeric forms. This category includes Ser225Phe
and Cys398Tyr. The mutant polypeptide reduces wild-type fXI polypeptide
secretion through formation of nonsecretable heterodimers (dominant-
negative effect). Het indicates heterozygote; and Hom, homozygote for fXI
gene mutation.
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and is, therefore, probably relatively common.
These observations suggest a 3-part mechanistic classiﬁcation
system for CRM fXI deﬁciency (Figure 2). The ﬁrst category
contains mutations that inhibit fXI polypeptide synthesis and
include nonsense mutations such as Glu117Stop,18 frame shifts,
deletions, splicing defects, and possibly amino acid substitutions
that cause severe polypeptide instability. A second category,
represented by the A4 domain substitutions Phe283Leu and
Gly350Glu,4,5,18 includes mutations that interfere with dimer
formation, resulting in intracellular retention of fXI as monomer.
Mutations in categories 1 and 2 are expected to cause little or no
interference with the product of the normal fXI allele (Figure 2).
The third category, which includes Gly400Val and Trp569Ser, and
now Ser225Phe and Cys398Tyr, contains mutations that form
nonsecretable homodimers and probably nonsecretable het-
erodimers with wild-type fXI. Saito et al16 noted that fXI levels
tend to be lower in non-Jewish patients heterozygous for fXI gene
mutations compared with their Jewish counterparts. The dominant-
negative effect proposed for category 3 explains this observation
and would account for some families with apparent autosomal-
dominant fXI deﬁciency.5,10,11,21
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